Harvard Bioscience, Inc.HBIONASDAQ
LOADING
|||
Switch Symbol:
EPS Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
41.75%
↑ 101% above average
Average (39q)
-7186.27%
Historical baseline
Range
High:969.57%
Low:-285100.00%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 41.75% |
| Q2 2025 | 95.48% |
| Q1 2025 | -285100.00% |
| Q4 2024 | 100.36% |
| Q3 2024 | -63.45% |
| Q2 2024 | 38.82% |
| Q1 2024 | -158.22% |
| Q4 2023 | -46.90% |
| Q3 2023 | -25.54% |
| Q2 2023 | -256.08% |
| Q1 2023 | 137.37% |
| Q4 2022 | 51.59% |
| Q3 2022 | -238.64% |
| Q2 2022 | 134.71% |
| Q1 2022 | -950.00% |
| Q4 2021 | 576.19% |
| Q3 2021 | 58.82% |
| Q2 2021 | 39.29% |
| Q1 2021 | -6.33% |
| Q4 2020 | 43.97% |
| Q3 2020 | 31.39% |
| Q2 2020 | 65.75% |
| Q1 2020 | 0.00% |
| Q4 2019 | -71.43% |
| Q3 2019 | -976.92% |
| Q2 2019 | 89.68% |
| Q1 2019 | -205.00% |
| Q4 2018 | 969.57% |
| Q3 2018 | 83.00% |
| Q2 2018 | 63.09% |
| Q1 2018 | -466.67% |
| Q4 2017 | 350.00% |
| Q3 2017 | -9.09% |
| Q2 2017 | 64.29% |
| Q1 2017 | 23.00% |
| Q4 2016 | 20.00% |
| Q3 2016 | -139.23% |
| Q2 2016 | -11.76% |
| Q1 2016 | 96.26% |
| Q4 2015 | -1900.00% |